SGLT2 Inhibitors: From Antihyperglycemic Agents to All-Around Heart Failure Therapy

Circulation. 2022 Jul 26;146(4):299-302. doi: 10.1161/CIRCULATIONAHA.122.060348. Epub 2022 Jul 25.

Authors

Stefan D Anker^{1

2}, Muhammad Shariq Usman³, Javed Butler^{3

4}

Affiliations

¹ Department of Cardiology and Berlin Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin, Germany (S.D.A.).
² Institute of Heart Diseases, Wrocław Medical University, Poland (S.D.A.).
³ Department of Medicine, University of Mississippi, Jackson (M.S.U., J.B.).
⁴ Baylor Scott and White Research Institute, Dallas, TX (J.B.).

PMID: 35877834
DOI: 10.1161/CIRCULATIONAHA.122.060348

No abstract available

Keywords: Editorials; clinical trials; diabetes; heart failure; mortality; sodium glucose co-transporter 2 inhibitors.

Publication types

Editorial
Comment

MeSH terms

Diabetes Mellitus, Type 2* / drug therapy
Glucose
Heart Failure* / drug therapy
Humans
Hypoglycemic Agents / therapeutic use
Sodium-Glucose Transporter 2
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

Hypoglycemic Agents
Sodium-Glucose Transporter 2
Sodium-Glucose Transporter 2 Inhibitors
Glucose